BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 49,600 shares, a growth of 81.0% from the December 31st total of 27,400 shares. Based on an average trading volume of 76,700 shares, the days-to-cover ratio is currently 0.6 days.

BrainsWay Stock Performance

BrainsWay stock traded up $0.16 during midday trading on Thursday, reaching $10.63. The stock had a trading volume of 10,405 shares, compared to its average volume of 54,616. The stock's 50-day simple moving average is $9.85 and its 200 day simple moving average is $8.94. The stock has a market capitalization of $199.86 million, a PE ratio of 106.26 and a beta of 1.23. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.25.

BrainsWay (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. The firm had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. During the same period in the prior year, the firm earned ($0.01) EPS. Equities analysts predict that BrainsWay will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of BrainsWay

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock worth $136,000 after purchasing an additional 11,221 shares during the last quarter. Rhumbline Advisers boosted its position in BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock valued at $207,000 after buying an additional 2,144 shares in the last quarter. Finally, Good Life Advisors LLC lifted its holdings in BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock worth $516,000 after buying an additional 22,080 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Monday, December 23rd. Northland Securities lifted their price objective on BrainsWay from $11.00 to $12.50 and gave the company an "outperform" rating in a research report on Thursday, October 3rd.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.